GlassScriptPhysician profile
Tyler Edward Russell
NPI 1497472591
$6,454.12
in general payments reported to CMS, 2019-2025
13 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,721 · 2024: $4,375 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Travel and Lodging: $1,585 · Consulting Fee: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.96 |
| Travel and Lodging | $1,585.16 |
| Consulting Fee | $1,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,600.22 | 2023-2025 | Biktarvy, Epclusa, Yeztugo |
| Viiv Healthcare Company | $996.51 | 2023-2025 | Cabenuva, Apretude, Rukobia |
| Abbvie INC. | $175.39 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $174.32 | 2023-2024 | Pifeltro, Delstrigo |
| Emd Serono, INC. | $138.08 | 2024 | Serostim |
| Astrazeneca Pharmaceuticals LP | $102.91 | 2023 | Evusheld |
| Novo Nordisk INC | $70.53 | 2024 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $70.27 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.13 | 2023-2024 | Xifaxan |
| Pfizer INC. | $25.10 | 2023 | |
| Hologic Sales and Service, LLC | $22.59 | 2025 | Thinprep 2000 Processor, Aptima |
| Paratek Pharmaceuticals, INC. | $18.86 | 2025 | Nuzyra |
| Collegium Pharmaceutical, INC. | $18.21 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.